Investor Presentation

Investor Presentation - Q2FY27 - Revenue 105.6bn +102.3% y-y; EBITDA 40.8bn +104.7% y-y; PAT 25.5bn +97.9% y-y - Business evolving into integrated pharma platform with capacity expansion, CDMO commercialisation, and new formulations - 21 DMFs filed globally; 3-5 new filings and 7 new APIs planned in FY27 - CDMO commercial supplies targeted from Q3 FY27; 8 new clean lines commissioning in Q1 FY28 adding 1,200 MTPA capacity - Strong export presence with 40+ countries; focus on regulated markets and backward integration - Recent acquisitions expanded manufacturing base and entry into formulations and biologics - EBITDA margin at 23.3% H1 FY27; PAT margin at 13.2% - Net cash from operating activities negative at 7.9bn H1 FY27 due to working capital changes - Debt-to-equity ratio improved to 0.2x in FY26, with increased equity base in H1 FY27